ThromboGenics NV (Euronext Brussels: THR) is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in-house expertise and collaborations with academic institutions to build a strong pipeline of promising drug candidates in cardiovascular diseases, visual disorders and cancer.

The Company plans to show proof-of-concept for its products by taking them through to completion of Phase II clinical trials. To leverage its expertise, ThromboGenics selectively forms development and marketing collaborations with experienced partners in the pharmaceutical industry. Such collaborations can lead to ThromboGenics generating revenues via milestone payments, as well as royalties on commercial sales.

ThromboGenics was founded by its Chairman, Professor Désiré Collen, a renowned expert in cardiovascular disease. The Company currently has around 50 people based at its headquarters in Leuven, Belgium, and at its facilities in Ireland and the U.S.